

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 8336 - MITSUBISHI CHEMICAL HOLDINGS / MARUBENI / METRO PACIFIC INVESTMENTS / JV

SECTION 1.2

Description of the concentration

This notification relates to the acquisition of joint control by LSI Medience Corporation ("LSI"), Marubeni Corporation ("Marubeni") and Metro Pacific Hospital Holdings, Inc. ("MPHHI") over a full-function joint venture which will provide clinical laboratory services and clinical reagents to hospitals in the Philippines.

LSI is a company registered in Japan, and is an indirect subsidiary of Mitsubishi Chemical Holdings Corporation (the holding company of the Mitsubishi Chemical group of companies (the "Mitsubishi Chemical Group"). LSI is, as part of the group's healthcare business unit, a direct subsidiary of Life Science Institute, Inc.. LSI provides various medical services worldwide (primarily, in Japan) including clinical testing; the development and provision of in-vitro diagnostic reagents and instruments; drug development support services; food sanitation analysis services and anti-doping testing services. The wider Mitsubishi Chemical Group provides various performance products, industrial materials and healthcare products worldwide (again primarily, in Japan) and is listed on the Tokyo Stock Exchange.

Marubeni is a company registered in Japan and is a leading wholesale provider of a range of industrial and consumer goods - specifically, food and consumer products; chemical and forest products; energy and metals; power projects and plants; transportation and industrial machinery. It is listed on both the Tokyo and Nagoya Stock Exchanges.

MPHHI is a company registered in the Philippines, and is a directly owned subsidiary of Metro Pacific Investments Corporation ("MPIC"), an investment and management holding firm which invests in and operates (through its subsidiaries) real estate and infrastructure projects in the Philippines. MPHHI is part of MPIC's hospital operations unit, operating and managing hospitals in the Philippines. MPIC is listed on the Philippines Stock Exchange.

The joint venture will supply clinical laboratory services and clinical reagents to hospitals in the Philippines. Specifically, it will:

-Provide clinical laboratory services, including (but not limited to) the following areas:
(i) clinical chemistry; (ii) immunochemistry; (iii) haematology/histology;
(iv) microbiology; (v) infectious immunology, and (vi) genetic testing.

-Sell clinical reagents including, if necessary, the sale and lease of equipment, materials, facilities and systems for which such clinical reagents are to be used. The types of reagents to be supplied include those relating to: (i) clinical chemistry; (ii) immunochemistry; (iii) haematology/histology; (iv) microbiology; (v) infectious immunology; (vi) genetic testing; (vii) pathology; and (viii) blood banks.

The transaction will be implemented by way of purchase of shares.